



Australian Government
Department of Health and Aged Care
Office of Drug Control

Cost Recovery Implementation Statement (CRIS)

Regulation of Medicinal Cannabis 2023 - 24

Effective from 1 July 2023



© Commonwealth of Australia

Ownership of intellectual property rights

Unless otherwise noted, copyright (and any other intellectual property rights, if any) in this publication is owned by the Commonwealth of Australia (referred to as the Commonwealth).

Creative Commons Licence

All material in this publication is licensed under a Creative Commons Attribution 3.0 Australia Licence, save for images, content supplied by third parties, and the Commonwealth Coat of Arms.

Creative Commons Attribution 3.0 Australia Licence is a standard form licence agreement that allows you to copy, distribute, transmit and adapt this publication provided you attribute the work. A summary of the licence terms is available at creativecommons.org/licenses/by/3.0/au/deed.en. The full licence terms are available at creativecommons.org/licenses/by/3.0/au/legalcode.

This publication (and any material sourced from it) should be attributed as: *Office of Drug Control, November 2023, Cost Recovery Implementation Statement Regulation of Medicinal Cannabis 2023-24 - prepared for the Office of Drug Control, Canberra.*

Inquiries regarding the licence and any use of this document should be sent to: mcs@health.gov.au.

Office of Drug Control

Postal address:

PO Box 100
Woden
ACT, 2606
Australia

Switchboard:

(02) 6289 1555

Web:

odc.gov.au

The Australian Government acting through the Office of Drug Control has exercised due care and skill in the preparation and compilation of the information and data in this publication. Notwithstanding, the department, its employees and advisers disclaim all liability, including liability for negligence, for any loss, damage, injury, expense or cost incurred by any person as a result of accessing, using, or relying upon any of the information or data in this publication to the maximum extent permitted by law.

Table of contents

1.	Introduction	4
1.1	Purpose of the Cost Recovery Implementation Statement	4
1.2	Single Convention on Narcotic Drugs	4
1.3	Review of cost recovery arrangements	5
1.4	Outline of the regulatory activities	6
2.	Policy and statutory authority to cost recover	7
2.1	Government policy approval to cost recover	7
2.2	Statutory authority to charge	8
3.	Cost recovery model	8
3.1	Outputs and business processes of the regulatory activity	9
	<i>Outputs</i>	9
3.2	Costs of the regulatory charging activity	16
	<i>Activity Based Costing</i>	16
	<i>Cost drivers and assumptions</i>	17
	<i>Non cost recoverable activities</i>	18
3.3	Design of regulatory charges	18
	<i>Fees</i>	18
	<i>Charges (Levies)</i>	18
	<i>Fees and charges – 1 to 31 July 2023</i>	19
	<i>Fees and charges – from 1 August 2023</i>	19
4.	Risk assessment	21
5.	Stakeholder engagement	21
6.	Financial Estimates	22
7.	Performance	22
7A.	Financial performance	22
7B.	Non-financial performance	23
	<i>Reasons for variances</i>	Error! Bookmark not defined.
	<i>Performance measures</i>	24
	<i>International Scrutiny</i>	24
8.	Key forward dates and events	25
9.	CRIS approval and change register	25

1. Introduction

Cost recovery involves government entities charging individuals or non-government organisations some or all the efficient costs of a regulatory activity. This may include goods, services or regulation, or a combination of them. The Australian Government Charging Framework (AGCF), which incorporates the Cost Recovery Guidelines (the CRGs)¹, sets out the framework under which government entities design, implement and review regulatory charging activities, consistent with the *Public Governance, Performance and Accountability Act 2013*.

The AGCF promotes consistent, transparent, and accountable charging for regulatory activities and supports the proper use of public resources. The Government's Charging Policy is based on the foundation that those who create the need for regulation, should bear the cost of that regulatory effort. The Australian Government have agreed to the 'Charging Policy Statement' that all charging arrangements must adhere to:

"Where specific demand for a government activity is created by identifiable individuals or groups, they should be charged for the costs of that activity unless the Government has decided to fund that activity".

The AGCF is the Government's policy outlining how a regulator determines costs and sets fees and charges for its regulatory activities. Fees for regulatory charging activities are set to only recover the minimum efficient costs of carrying out that regulatory activity. The Medicinal Cannabis Program's cost recovery arrangement aligns with the AGCF and the CRGs.

1.1 Purpose of the Cost Recovery Implementation Statement

This Cost Recovery Implementation Statement (CRIS) provides information on how the Department of Health and Aged Care (the Department) implements cost recovery for activities associated with the Medicinal Cannabis Scheme (the Scheme) under the *Narcotic Drugs Act 1967* (the Act). It also reports financial and non-financial performance information for the Scheme and contains financial forecasts for the 2023-24 financial year and three forward years.

Revised fees and charges were implemented from 1 August 2023, following the associated regulation amendments by the Australian Government.

The Department will maintain the CRIS until the activity or cost recovery for the activity is discontinued.

1.2 Single Convention on Narcotic Drugs

Australia is a party to the Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol (the Single Convention). This convention aims to limit harm from illicit use or abuse of narcotic drugs while setting out the scope of permitted activities, such as for medical and/or scientific use.

As a party to the Single Convention, there are two key responsibilities for the Australian Government. The first is an obligation to carefully control, supervise and report on cultivation, production, and manufacture of narcotic drugs, including medicinal cannabis. The second is to take measures to prevent the stockpiling or diversion of narcotic drugs, including medicinal cannabis, for illicit purposes.

¹ The Australian Government Charging Framework and the CRGs are available on the Department of Finance website (www.finance.gov.au).

The Act was enacted in 1967 to give effect to certain of Australia's obligations under the Single Convention. Significant amendments were made to the Act in 2016 to allow for the establishment of the Scheme and provide a pathway for lawful supply of medicinal cannabis to Australian patients. The amended Act was designed to ensure that Australia will remain compliant with its international treaty obligations in the Single Convention.

In accordance with the Single Convention, the Office of Drug Control (ODC) within the Department of Health and Aged Care (the Department) is the agency that has sole responsibility for the regulation of the cultivation and production of medicinal cannabis for medicinal and research purposes. No other Government agencies are involved in this partial cost recovery arrangement. The Department implemented and continues to administer the Scheme, which includes a licence and permit framework that allows for the cultivation, production, and manufacture of medicinal cannabis in Australia. The Scheme helps ensure Australian patients have access to essential medicine while supporting the Australian Government's policy of harm minimisation.

1.3 Review of cost recovery arrangements

The Government has passed legislation to enable the utilisation of cannabis for medicinal and scientific purposes. A detailed regulatory framework has been implemented to enable applications for licences and permits for the cultivation, production and manufacture of medicinal cannabis products. For the purposes of this document, the Scheme's cost recovery arrangements apply to:

- medicinal cannabis licences, for any one or more of cultivation, production and manufacture activities
- medicinal cannabis permits relating to cultivation and production activities
- medicinal cannabis permits relating to manufacture activities, and
- compliance activities related to such licence and permit holders.

On 24 December 2021, amendments to the Act, made by the *Narcotic Drugs Amendment (Medicinal Cannabis) Act 2021* (the 2021 Amendments), came into effect to implement certain recommendations from the *Review of the Narcotic Drugs Act 1967* undertaken by Professor John McMillan AO in 2019. The 2021 Amendments implemented a single, perpetual licence model for medicinal cannabis regulation, replacing the previous structure of requiring separate medicinal cannabis licences for different activities. Related permit reforms were also implemented. These broader reforms also resulted in the need for changes to the Scheme's fees, charges, and cost recovery arrangements.

As a result, during 2022, the ODC undertook a review of the existing medicinal cannabis cost recovery arrangements, including the level at which fees and charges were set, in accordance with the AGCF and in consultation with stakeholders. As part of the review, a new activity-based costing model was developed to calculate the appropriate fees and charges to be applied in line with the 2021 reforms that implemented a single licence framework and permit reforms. This comprehensive review determined the minimum efficient costs of regulation. The review identified that the previous cost recovery arrangements, which were seen as fit-for-purpose when developed in 2016-17, only recovered part of the full regulatory cost of the revised activities under the single licence program.

In the 2023-24 Budget, the Government approved revised cost recovery arrangements to reflect the regulatory effort, or associated costs, of managing the new single licence program and to align with the AGCF.

Under the revised cost recovery arrangements some fees have increased, and some have decreased with respect to a new licence and permit variation structure. The monitoring and compliance structure was also amended to apply specific inspection charges in part due to the removal of the annual site charge.

The resulting changes to fees and charges commenced on 1 August 2023.

Cost recovery for the regulation of the Scheme aligns with the Government's overarching cost recovery policy which is, where appropriate, non-government recipients of specific government activities should be charged some or all of the costs of such activities. The cost recovery policy promotes consistent, transparent, and accountable charging for Government activities and supports the proper use of public resources. Fees and charges are imposed on applicants and licence holders who engage with the Scheme.

1.4 Outline of the regulatory activities

Medicinal Cannabis Licences

An applicant may make an application for a licence to undertake one or more of medicinal cannabis cultivation, production or manufacture activities. The Secretary of the Department or a Delegate of the Secretary (a Delegate) must make a decision on that application. In deciding, the Delegate must be reasonably satisfied with the following factors:

- the applicant, and the applicant's relevant business associates, must be considered fit and proper persons to either hold a licence or be associated with a licence. This involves consideration of a range of matters including criminal history, connections, associates and family, financial status, business history and capacity to comply with licensing requirements. Licence holders are to remain 'fit and proper' for the duration of the licence. This test is explicitly designed to ensure the exclusion of persons who may be tempted to use the Scheme as cover for illegal activities.
- it must be established that the applicant can maintain the physical security of the cannabis plants, cannabis, or cannabis resin and/or medicinal cannabis drug.

Medicinal Cannabis Permits

Once a licence is granted, a licence holder must undertake the activities authorised under the licence in accordance with one or more permits. A licence holder must submit a permit application and a Delegate must make a decision on that application. In deciding to grant a permit, the Delegate will set limits on the scope of the activities that can be undertaken, such as:

- the quantity of cannabis plants that can be cultivated
- the quantity of cannabis and/or cannabis resins that can be produced
- the maximum quantity of the drug that may be manufactured.

Additionally, it must be established that a legitimate supply arrangement exists between the applicant for a medicinal cannabis permit and the holder of a licence to produce or manufacture medicinal cannabis. This is to prevent the diversion of cannabis and to ensure that the activities are related to the medicinal use of cannabis.

Cannabis permits are only granted for production where there is a contract between the licence holder and an authorised producer or licensed manufacturer. Permits are granted for a 12-month period and require subsequent applications to be submitted and approved to continue permitted activities. This assists in meeting a key obligation of the Single Convention to prevent over-production and diversion to illicit uses.

Monitoring and Compliance

Cannabis licences are subject to statutory conditions and a Delegate can impose conditions on the licence to promote security of the crop, cannabis, and cannabis resins, so that it is not diverted to illicit uses. Substantial penalties exist for contravention of these conditions and offences relating to activities that are not authorised by the medicinal cannabis licence.

Regulatory Enabling Services

The ODC delivers a range of enabling services that directly supports the regulation of medicinal cannabis, including the development and implementation of governance, policy and procedural materials, legislative reforms to streamline the regulatory framework, data analytics, program reporting and Government briefings, enquiries management and intergovernmental agreements with law enforcement and other Commonwealth, state and territory agencies. In addition, the ODC delivers a range of financial management services associated with the fees and charges applied to the regulation of medicinal cannabis licence holders.

Excluded Activities for this CRIS

For clarity, the following activities are not included in the Scheme's cost recovery arrangements as they are conducted under separate legislation:

- costs for activities related to the import and export of medicinal cannabis under the *Customs (Prohibited Imports) Regulations 1956* and the *Customs (Prohibited Exports) Regulations 1958*.
- costs for activities authorised under the *Therapeutic Goods Act 1989*, such as licences to manufacture therapeutic goods (under Part 3-3 of that Act) and costs for patient access to medicinal cannabis drugs through the Therapeutic Goods Administration's (TGA's) Authorised Prescriber Scheme and Special Access Scheme.

2. Policy and statutory authority to cost recover

2.1 Government policy approval to cost recover

In the 2015-16 Mid-Year Economic and Fiscal Outlook, the Government announced its intention to establish a Commonwealth licensing scheme, to be administered by the Department², to regulate the cultivation of cannabis for medicinal and scientific use.

Additionally, in the 2016-17 Budget, the Government announced that it would introduce legislation to allow charges to be imposed on cannabis-related licences granted under the Act. Any revenue collected will support the Scheme for the regulation of cannabis for medicinal and scientific use.

Given the greater than anticipated interest in the Scheme, in the 2018-19 Mid-Year Economic and Fiscal Outlook, the Government increased resourcing to administer the Scheme and required the

² Mid-Year Economic and Fiscal Outlook 2015-16, https://archive.budget.gov.au/2015-16/myefo/MYEFO_2015-16_Final.pdf, p.180.

Department to review the cost recovery arrangements³. As a result of the review, the Department developed a proposal for amendments to fees and charges for the Scheme and undertook a detailed program of stakeholder engagement.

In the 2020-21 Budget, the Government announced the extension of cost recovery arrangements to medicinal cannabis-related manufacture licences and increased resourcing to meet the ongoing demands of administering the Scheme. Changes to fees and charges were outlined that commenced on 1 November 2020.

In the 2023-24 Budget, the Government approved revised cost recovery arrangements to align cost recovery fees and charges with the associated costs of managing the single, perpetual licence model for medicinal cannabis regulation and revised permits framework.

There are no changes to the partial cost recovery arrangements that relate to non-commercial medicinal cannabis licences. It was determined that full recovery may reduce investment in research. The shortfall in costs will continue to be met through appropriation from the Australian Government.

2.2 Statutory authority to charge

The Act⁴ allows for regulations that provide for the imposition of fees for any matters within it, including matters relating to the payment of fees and charges. *The Narcotic Drugs Regulation 2016* (Narcotic Drugs Regulation) is the instrument that specifies the fees related to applications and inspections.

The *Narcotic Drugs (Licence Charges) Act 2016* (Licence Charges Act) provides authority to impose a charge on a licence granted under the Act and that is in force within a specified period. The licence charge assists the Commonwealth in recovering the costs of the administration, monitoring and assessment of compliance with the requirements of the Act, the Narcotic Drugs Regulation, the licence and any permits. Section 8 of the Licence Charges Act allows regulations to prescribe the amount of charges.

The *Narcotic Drugs (Licence Charges) Regulation 2016* (Licence Charges Regulation) specifies the period the charge is imposed, the amount and how the charge is calculated. It also provides for non-commercial medicinal cannabis licence holders to pay one licence charge for the period for which the licence is in force, instead of for each 12-month period that the licence is in force as with perpetual commercial medicinal cannabis licences. A non-commercial medicinal cannabis licence is defined in section 54A of the Narcotic Drugs Regulation. Non-commercial medicinal cannabis licences are generally not perpetual but issued for a relevant period related to the research project timeline to be undertaken.

3. Cost recovery model

The cost recovery arrangements provide for the imposition of both fees and levies (charges). The characteristics of a government activity determine the type of cost recovery charge used. There are two types of cost recovery charges, fees and levies:

Cost recovery fees will be charged where a direct relationship exists between the regulatory activity and the individual or organisation requesting that specific activity. All regulated entities

³ Mid-Year Economic and Fiscal Outlook 2018-19, https://archive.budget.gov.au/2018-19/myefo/myefo_2018-19.pdf, p.189.

⁴ *Narcotic Drugs Act 1967*, Section 28 (1)(c), (d) and (e).

are charged the same fee for the same activity. Under these circumstances, the activities performed, and their associated costs are driven by a specific need and demand created by the applicant. For example, applications for a Medicinal Cannabis licence will be charged a cost recovery fee.

A cost recovery fee is also payable for an inspection undertaken in relation to an application for a licence, permit or a licence/permit variation application (an application-based inspection).

Cost recovery charge (levy) will be charged when the cost of the activity can be reasonably attributed to a broader group of organisations (or individuals) rather than a single entity. In these instances, the level of demand for Government activity or intervention is collectively driven by the industry as a whole rather than a single entity within it.

Inspection Levy (e.g., Specific Cost Recovery Levy) – a charge that recovers the minimum efficient costs of routine regulatory inspections and verifications. This cost recovery charge is based on the regulatory cost associated with the administering and conducting of inspections or verification activities (such as for tip-offs). It is proposed that the charge will be imposed at the point-in-time the inspection or verification occurs.


3.1 Outputs and business processes of the regulatory activity

Outputs

The activity-based cost recovery model has been developed based on the key business activities that result in a number of outputs. Each output is delivered through the completion of tasks or staff effort.

Figure 1 is a condensed example of the activities, outputs and tasks, the respective effort, and whether costs are recovered. This is not a complete list of all activities and outputs, rather it is an illustration of some business processes.

Figure 1: Condensed ODC Business Processes



3.1.1 Output 1 - Applications

The Scheme allows for several different applications that have similar processes. However the effort and time required for each process varies depending on the nature of the application.

The process related to an application is as follows:

- receipting - which includes filing all documentation and handling payment of invoices
- qualitative screening of the applications
- assessment of the application
- decision by a delegate to grant or refuse to grant a medicinal cannabis licence, permit, or variation to a medicinal cannabis licence or permit
- notification of decision made.

Application for a medicinal cannabis licence

Any person interested in undertaking cultivation, production, or cannabis-related manufacture under the Scheme must apply for a medicinal cannabis licence authorising any or all of these activities and a Delegate must make a decision on the application. While each medicinal cannabis licence application considers different information that reflects the nature of the activity to be authorised, the Department's internal cost recovery review found that, in general, the average efficient time for assessing an application is comparable.

The assessment of a medicinal cannabis licence application includes consideration of the applicant as a fit and proper person to hold a licence, the ability of the applicant to maintain security of the cannabis, cannabis resin or cannabis drugs, and alignment of the proposed activities with Australia's obligations under the Single Convention.

Application to vary a medicinal cannabis licence

A licence holder can apply to vary a medicinal cannabis licence. The effort required for the handling of such an application differs significantly, depending on the nature of the variation. In order to streamline the design of fees, the significant variable regulatory effort was identified in licence variations and have been established to group similar effort into the same fee amount. Licence holders will be required to pay for each variation requested to a licence or permit. In circumstances where multiple variations to a licence or permit are requested, the applicant will pay for each variation applied for. As a result, the application fee to vary a medicinal cannabis licence is divided into four categories with differing costs:

- licence variation type 1 – an application to vary a medicinal cannabis licence for any of the following purposes
 - to change the licence holder name
 - vary or remove authorised persons from a licence
- licence variation type 2 – an application to vary a medicinal cannabis licence for any of the following purposes
 - change period in which a licence is in force (for non-commercial licence holders)
 - vary, add, or remove particular measures to the system of security
 - any other non-specified requirements
- Licence variation type 3 – an application to vary a medicinal cannabis licence for any of the following purposes
 - vary the layout of site
 - vary the floorplan of facility
 - vary, add, or remove a particular activity authorised by the licence
 - add one or more authorised person/s
- Licence variation type 4 – an application to vary a medicinal cannabis licence for the following purpose
 - add additional licensed site.

Application for a medicinal cannabis permit

Any activities authorised under a medicinal cannabis licence must be undertaken in compliance with a valid cannabis permit. As such, once a medicinal cannabis licence is granted, a licence holder may apply for one Cultivation and Production Permit and/or one Manufacture Permit, per site. If an initial permit is granted, the permit will be active for a 12-month period. Should the

licence holder want to continue activities under a permit following the 12-month initial permit period, a subsequent permit application for the next 12-month period is required for submission.

Medicinal cannabis permits are used to control the quantities of cannabis plants cultivated, cannabis or cannabis resin produced and quantities of cannabis drugs that are manufactured. A medicinal cannabis permit is a critical tool in ensuring Australia complies with its international obligations under the Single Convention. The assessment of a medicinal cannabis permit will verify that the source/s of the cannabis plants, cannabis or cannabis resin are licit and require evidence of contracts between entities that are supplying or receiving cannabis plant, cannabis, or cannabis resin.

During the review of cost recovery arrangements, it was evident that there is more regulatory effort expended on initial permit applications than there is on subsequent permit applications for both Cultivation and Production and for Manufacture permits, therefore separate fees exist. As a result, the application fee to apply for an initial and subsequent Cultivation and Production Permit, and a Manufacture Permit, is divided into 4 categories:

- Permit application (Cultivation and Production) – Initial
- Permit application (Cultivation and Production) – Subsequent
- Permit application (Manufacture) – Initial
- Permit application (Manufacture) - Subsequent

Applications to vary a medicinal cannabis permit

As with a medicinal cannabis licence, a licence holder can apply to vary a medicinal cannabis permit and the effort associated with handling that application differs significantly in the nature of the variation. These fees have been structured to reflect the regulatory effort required to administer these variations. Similar to licence variations, permit holders will be required to pay for each variation requested. Similarly, the application fees to vary a medicinal cannabis permit is divided into three categories:

- Permit variation type 1 - application to vary a medicinal cannabis permit for any of the following purposes:
 - to change the licence holder name
 - change to maximum quantity at any one time with no change to total quantity
- Permit variation type 2 - application to vary a medicinal cannabis permit for the following purpose:
 - add or remove a particular supply pathway specified by the permit
- Permit variation type 3 - application to vary a medicinal cannabis permit for the following purpose:
 - change to total quantities, type of cannabis plants, total number of cannabis plants, or total units of seeds
 - vary, add, or remove a particular activity specified by the permit

3.1.2 Output 2 - Inspections

An inspection is undertaken to verify matters relating to medicinal cannabis licences or permits. It is Departmental policy that two Authorised Inspectors attend all inspections given the potential seriousness of the non-compliance and all charges are indicative of this effort. The manner in

which the costs of inspections are recovered varies depending on the context of the inspection and effort undertaken.

Specific inspection charges will apply to monitoring and inspection events. These specific cost recovery charges recover the minimum efficient costs of regulatory inspections and verifications. This cost recovery charge is based on the regulatory cost associated with the administering and conducting of routine regulatory inspections or verifications (either virtually/desktop or onsite). It is proposed that the charge will be imposed at the point-in-time the inspection or verification occurs.

Application-Based Inspection (Inspection Fee)

Upon an application being made for an initial cannabis permit, and prior to making a decision on the application, the Department will conduct an application-based inspection of the premises. This is to inform the decision on the permit application by ensuring that the site is ready for operation by being compliant with the conditions of the medicinal cannabis licence and being in accordance with the proposed site/facility plans provided with the application. An application-based inspection can also be required in relation to other types of licence/permit related applications, as determined by a risk-based compliance approach.⁵ An application-based inspection is subject to an inspection fee as they are in direct response to a request from an individual or organisation.

Historical data has demonstrated that permit application-based inspections occur within a similar timeframe and are usually shorter in duration compared to compliance monitoring inspections, in particular for an inspection related to an initial permit application as there will be no cannabis plants, cannabis, or cannabis resin on site at the time of such an inspection.

Monitoring and Compliance Inspection Type 1 and Type 2

Every licence holder is subject to routine regulatory compliance monitoring inspections on an ongoing basis once a licence has been granted, whereby Authorised Inspectors undertake an inspection using monitoring powers as outlined under Division 2, Subdivision A of the *Regulatory Powers (Standard Provisions) Act 2014* (the Regulatory Powers Act). Associated costs are included in the routine regulatory (inspection type 1) or verification (inspection type 2) inspection charges (levies), depending on the matter. The inspection type 1 and type 2 charges will be imposed at the point in time the inspections take place.

A verification inspection is undertaken to verify the veracity of information, for example to verify information received through public concern (tip-offs) or to verify actions undertaken by the licence holder.

Inspection related travel costs

Applicants and licence holders will not pay any inspection related travel costs. The Department has been provided appropriated funding for this cost, to remove any financial disadvantage for applicants, or licence holders in rural or remote locations who would be subject to higher travel costs based on their location.

Inspection related travel costs include accommodation, airfares, train fares, car hire, taxi or other car services, tolls, meals, or other allowances for departmental employees, and whole of government booking fees.

⁵ [Risk management approach to the cultivation, production and manufacture of medicinal cannabis | Office of Drug Control \(odc.gov.au\)](#) 2021.

Testing of cannabis samples

During an inspection, an Authorised Inspector has the power to gather samples of cannabis or cannabis resin and take that sample for testing. Samples are tested at the TGA's laboratories to determine the cannabinoid content of the cannabis and verify if the test results comply with the cannabinoid content listed on the relevant cannabis permit. The cost of undertaking these tests is \$1,230 and this is passed directly to the licence holder.

3.1.3 Output 3 – Annual licence charge

Annual licence charge

An annual charge is applied to recover the costs of specific activities that are essential for robust regulation of the sector. The annual charge applies to all licence holders irrespective of whether they hold permits or not. These costs exist irrespective of the number of licences or permits approved. These activities include, but are not limited to, enquiries management; web services and IT costs; industry education including compliance campaigns; and regulatory governance including enquiries and financial management, conducted by the ODC to ensure it meets the policy and legislative responsibilities in delivering efficient regulation.

More specific detail is set out below on some of the activities the cost of which are included in the annual licence charge, namely:

- response to mandatory notification
- licence suitability review
- regulatory governance
- compliance education campaigns
- continuous improvement.

3.1.3.1 Response to mandatory notification

In accordance with section 10K of the Act and section 20 of the Narcotic Drugs Regulation, it is a condition that all licence holders notify a Delegate of certain matters. As the Department must respond to these notifications, the cost of such responses is included in charges to licence holders. Not all matters relate to non-compliance. However, the Department must review each matter and respond accordingly.

Some of the matters that a licence holder must notify a Delegate of relate to the loss or theft of cannabis plants, cannabis, or cannabis resin. Other matters relate to the licence holder itself, such as notification of new shareholders and business associates. As a result, the recovery of costs associated with a response to mandatory reporting is assigned to the annual charge.

The following activities are associated with a response to mandatory notification:

- receive and register the notification
- review and analyse the notification
- make a determination on the matter
- refer matter of potential non-compliance to the relevant team for action (where relevant)
- notify licence holder of outcome

3.1.3.2 Licence suitability review

The recent legislative reforms introduced a single medicinal cannabis licence with perpetual operation. This means that the licence continues without an end date, but subject to the operation of the suspension, revocation and voluntary surrender frameworks in the Act and the Regulation.

Nevertheless, periodic reviews of a licence holder's circumstances will be undertaken to ensure the licence holder's information and records are up to date and that the licence holder continues to be suitable to hold the licence. This will include requesting and assessing information relevant to whether the licence holder continues to be fit and proper person/s and to ensure the licence and permit are up to date and do not require specific variation.

3.1.3.3 Regulatory governance

Review of mandatory cannabis permit reporting

Once a cannabis permit is granted, permit holders are obliged to provide reports on their activities in accordance with that cannabis permit. The Department will assess these reports on a quarterly basis as follows:

- receive and register reports
- review and analyse the report/s
- make determination on matter
- where relevant, refer matter of potential non-compliance to the relevant team for action
- notify licence holder of outcome.

Enquiries management

To ensure medicinal cannabis stakeholders have proper guidance, advice, and information to readily submit complete applications, as well as recognising the obligations of all licence holders, there is significant regulatory effort to respond to and manage enquiries. As the ODC must respond to these enquiries and can often lead to complex discussions, consultations, and further requests for information, the costs of this effort is included in the annual licence charge.

Financial management

The ODC undertakes many activities required to invoice appropriate fees and charges, negotiate payment plan arrangements, manage debt recovery, facilitate education and guidance regarding fees and charges, and manage the cost recovery arrangements. The cost of this effort is included in the annual licence charge that applies to all licence holders.

3.1.3.4 Education and compliance campaigns

As the result of an inspection, virtual (desktop) audit, cannabis permit report or a follow up audit, the Department may identify actions or behaviours on the part of a licence holder that, while not a matter of non-compliance, raises some concerns. In these instances, the Department may elect to undertake an educative approach with the licence holder or seek that the licence holders take corrective actions. Compliance related educative campaigns may be undertaken across wider groups of licence holders or the industry in relation to particular issues.

The following activities are associated with this business process:

- receive and review matter
- liaise with licence holder
- where relevant, provide documentation outlining corrective action to licence holder
- reconcile evidence that corrective action has been undertaken
- refer matter of potential non-compliance to the relevant team for action (where relevant) notify licence holder of outcome.

3.1.3.5 Continuous improvement

To ensure that the Department remains an agile and responsive regulator, the costs of undertaking continuous improvement of the Scheme by the Department has been incorporated into the cost recovery arrangements.

The following activities are associated with this business process:

- development and maintenance of publicly available guidance
- stakeholder engagement activities
- activity based costing processes and ongoing management of the cost recovery arrangements.

3.2 Costs of the regulatory charging activity

Activity Based Costing

An activity-based costing exercise was undertaken to determine the average efficient time spent by a departmental employee on each task. During the review of the Medicinal Cannabis Program Regulatory Fees and Charges, staff effort was identified against 555 tasks relevant to the single perpetual licence framework and permit reforms. Staff effort has been validated and quality assured to ensure that only the minimum regulatory effort is recorded to deliver each task at the proficient officer level. This process included accounting for the time spent across tasks such as medicinal cannabis licence and permit application assessments and compliance inspections. This allowed the Department to determine the direct and indirect costs of regulating the Scheme. Some indirect costs, such as the Secretariat function for the Medicinal Cannabis Expert Working Group, have not been included within the cost recovery arrangements and appropriation funding has been provided by the Government.

It is government policy that fees and charges are indexed annually to reflect the efficient costs of providing the services and undertaking the activities required to regulate the medicinal cannabis industry. However, the fees and charges were not indexed in 2022-23 due to the review of the cost recovery arrangements being conducted in accordance with the Australian Government Charging Framework and considering the revised legislative framework that commenced in December 2021.

The revised costs associated with the 2023-24 activity- based costing model incorporates an indexation strategy in line with the government policy.

The activity-based costing model will be reviewed annually, prior to the commencement of the financial year. Any efficiencies identified in the regulatory process will be reflected in the fees and charges set for the new financial year.

Cost drivers and assumptions

In determining the cost drivers, several assumptions were made based on historical data and experience from undertaking such activities. The Department has forecast the expected volumes of applications within the single licence framework, the time taken to undertake specific activities and the behaviours of the medicinal cannabis sector in determining the forecast volumes. For example, the Department determined forecast volumes of subsequent permit applications based on the relevant active permit numbers and the 12-month period each permit is granted for.

These estimates are highly sensitive to the growth of both the domestic and global medicinal cannabis markets, which are limited by the requirements of the Single Convention and regulated by the International Narcotics Control Board (INCB).

Tables 1 and 2 summarise the direct and indirect costs of each fee and charge for the 2023-24 financial year. Note that the final amounts of each fee and charge is rounded to the nearest \$10, as set out in tables 3 to 5 below.

Table 1: Unit Cost for 2023-24			
Output 1 - Applications	Direct costs	Indirect costs	Unit costs
New Licence Application	\$ 10,381	\$ 2,836	\$ 13,217
Licence Variation Type 1	\$ 457	\$ 122	\$ 579
Licence Variation Type 2	\$ 1,157	\$ 315	\$ 1,472
Licence Variation Type 3	\$ 1,708	\$ 466	\$ 2,174
Licence Variation Type 4	\$ 9,359	\$ 2,600	\$ 11,959
Permit Application (Cultivation and Production) – Initial	\$ 9,565	\$ 2,340	\$ 11,905
Permit Application (Cultivation and Production) – Subsequent	\$ 7,092	\$ 1,974	\$ 9,066
Permit Application (Manufacturing) – Initial	\$ 6,314	\$ 1,546	\$ 7,860
Permit Application (Manufacturing) – Subsequent	\$ 4,685	\$ 1,297	\$ 5,982
Permit Variation Type 1	\$ 488	\$ 130	\$ 618
Permit Variation Type 2	\$ 1,308	\$ 349	\$ 1,657
Permit Variation Type 3	\$ 4,031	\$ 1,104	\$ 5,135

Table 2: Unit Cost for 2023-24			
Output 2 - Inspections	Direct costs	Indirect costs	Unit costs
Application Based Inspection (Inspection fee)	\$ 7,488	\$ 1,741	\$ 9,229
Routine/Ongoing Inspection (Inspection type 1)	\$ 10,205	\$ 2,394	\$ 12,599
Inspection (Verification) (Inspection type 2)	\$ 3,865	\$ 895	\$ 4,760
Output 3 – Annual licence charge			
Annual licence charge	\$ 23,218	\$ 4,304	\$ 27,522

Non cost recoverable activities

The non-recoverable activities are those activities that cannot be directly attributable to the regulation costs of Licence holders. There are several regulatory administrative activities that are not cost recoverable within the context of the AGCF. These administrative items include Administrative Appeals Tribunal costs, providing advice to Government, Expert Working Group, moderate and major investigations, and prosecuting court action enforcements. Non cost recoverable items are funded by the Australian Government.

3.3 Design of regulatory charges

Australian Government policy is that it will charge the non-government sector some or all the efficient costs of specific government activities. The characteristics of a government activity determine the type of cost recovery charge used.

Fees

The Department uses fees to recover costs when services are provided directly to an individual applicant or licence holder. A fee is applicable where the activity is driven by an action of the applicant or licence holder.

All licence and permit applications and variations are subject to an application fee, to be paid by the applicant. An Application Based Inspection is also subject to a fee as they are in direct response to a request from an individual or organisation.

Charges (Levies)

There are two types of charges (levies) imposed on Licence Holders:

- **Annual Charge** - The annual charges (levies) are associated with costs that are not driven by the actions of individuals or entities, rather these pertain to the industry. As these outputs are delivered irrespective of the size, complexity or the regulatory maturity of the licence holder, the total annual costs of leviable outputs are shared between all licence holders. The proxy used to distribute the annual leviable costs will be the number of licence holder as of 31 March each year. On 31 March 2023 there were 95 licence holders.
- **Monitoring and Inspection Charges** - The costs of activities relating to the monitoring or response to potential or actual non-compliance of a licence holder are recovered using

Monitoring and Inspection charges. There are several types of inspections that the ODC can conduct – each based on the costs of undertaking the inspection.

To provide reduced regulatory costs, non-commercial medicinal cannabis licence holders are only required to pay the annual licence charge once during the period of the licence, compared with the requirement for commercial licence holders to pay these charges annually (commercial licences being perpetual). The shortfall in revenue for each non-commercial medicinal cannabis licence is met by appropriation funding from government.

Fees and charges – 1 to 31 July 2023

The 2021-22 fees and charges remained unchanged in the 2022-23 financial year. Following the review of the cost recovery arrangements, the approved changes to fees and charges have applied from 1 August 2023.

Fees and charges – from 1 August 2023

Licence Fees

Table 3 outlines the fees payable for new licence applications and four types of licence variation fees, as well as the forecast volumes and revenues for the 2023-24 financial year.

Table 3: Licence Fees Structure			
Pricing Points	2023-24 Amount	Estimated Volume	Estimated total revenue
New Licence Application	\$ 13,220	25	\$ 330,500
Licence Variation Type 1	\$ 580 each	10	\$ 5,800
- Change licence holder name - Remove authorise persons from Licence			
Licence Variation Type 2	\$ 1,470 each	29	\$ 42,630
- Change period in which licence is in force - Vary or remove a particular condition of the licence - Modify, add new, or remove security measures - Any other non-specified requirement			
Licence Variation Type 3	\$ 2,170 each	66	\$ 143,220
- Change of layout of site - Change of floorplan of facility - Add activity to Licence - Add authorised person/s			
Licence Variation Type 4	\$ 11,960 each	5	\$ 59,800
- Add Additional Site			

Whilst licence variations have been grouped together into respective types reflecting similar regulatory effort, each variation requested would include the relevant variation type price. For example, if a Licence Holder sought two different variations from Licence Variation Type 3 in 2023-24, the applicant would be charged \$2,170 for each variation sought paying a total of \$4,340.

Permit Fees

Table 4 outlines the fees payable for permit applications and variations as well as the forecast volumes and revenue for the 2023-24 financial year.

Table 4: Permit Fees Structure			
Pricing Points	2023-24 Amount	Estimated volume	Estimated total revenue
Permit Application (Cultivation and Production) – Initial	\$ 11,910	7	\$ 83,370
Permit Application (Cultivation and Production) – Subsequent	\$ 9,070	32	\$ 290,240
Permit Application (Manufacturing) – Initial	\$ 7,860	5	\$ 39,300
Permit Application (Manufacturing) - Subsequent	\$ 5,980	13	\$ 77,740
Permit Variation Type 1	\$ 620 each	5	\$ 3,100
- Change to licence holder name - Change to maximum quantity at any one time with no change to total quantity			
Permit Variation Type 2	\$ 1,660 each	6	\$ 9,960
- Change to supply pathways only			
Permit Variation Type 3	\$ 5,140 each	34	\$174,760
-Change to quantities or activities			

Similar to licence variations, each variation request would attract the relevant variation type fee amount and would be invoiced cumulatively.

Annual licence charge

Table 5 outlines the 2023-24 annual charge, the number of licence holders on 31 March 2023 and the forecast revenue for the 2023-24 financial year.

Table 5: Annual Charge Structure			
Pricing Point	Charge	Estimated volume	2023-24 Estimated total revenue
Annual Charge	\$ 27,520	95	\$ 2,614,400

Monitoring and Compliance Inspections

The structure for monitoring and inspections charges are detailed in Table 6. Inspections have been categorised into three key inspection types:

- Application Based Inspection used when conducting application-based inspections.
- Routine/ongoing inspections used for compliance monitoring purposes, and which are also based on the minimum efficient costs of conducting these inspections.
- Verification Inspections⁶ used when an inspection is required to verify that licence or permit conditions or legislative requirements have been met.

Table 6: Structure and Revenue from Monitoring and Inspection charges for 2023-24			
Pricing Point	Charge	Estimated volume	Estimated total revenue
Application based inspection (Inspection fee)	\$ 9,230	16	\$ 147,680
Routine/Ongoing Inspection (Inspection type 1)	\$ 12,600	41	\$ 516,600
Inspection (Verification) (Inspection type 2)	\$ 4,760	3	\$ 14,280

⁶ Verification inspections are either virtual or onsite inspections to verify veracity of information received or actions undertaken by the licence holder.

Forecast volumes

Volumes for licences and permits activities and outputs have been based on existing program data information, including predictions in the number of different licence and permit applications. Variation volumes have also been based on existing data sources.

Forecast volumes will be reviewed on an annual basis and any updates will occur as part of the annual CRIS review. Depending on their materiality they may impact on fees and charges.

4. Risk assessment

A Charging Risk Assessment for the Scheme has been undertaken resulting in a **MEDIUM RISK** rating. This rating is attributed to:

- change in structure of existing cost recovery arrangements; and
- the use of fees and levies

The impact on fee payers is considered medium risk for the following reasons:

- the annual site charge has been removed
- some activities have reduced fees and charges, whilst other regulatory charges have increased
- all fees and charges now more accurately reflect the minimum efficient costs of regulatory activity within the single licence framework
- no complex legislative changes were required
- stakeholders were consulted in late 2022, and no significant issues of concern were raised regarding the reformed fees and charges.

5. Stakeholder engagement

On 24 December 2021, various changes to the Act came into effect, including the introduction of a single licence model for cultivation, production and/or manufacture activities. At this time the ODC also implemented simpler permit processes and administrative reforms to reduce regulatory burden. These changes were implemented following the Medicinal cannabis reform – single licence reform (Information session) held on 13 October 2021. ODC contacted all existing licenced entities from October 2021 to confirm their details and ensure the entities were aware of the transition process. The ODC worked closely with each licence holder throughout the licence/permit transition process including to issue them with revised instruments.

Following these reforms, the existing cost recovery arrangements were reviewed, including the level at which fees and charges are set. In doing so it has become evident that some regulatory effort was not included in the existing fees and charges for the medicinal cannabis Scheme. The outcome of the review has informed the Australian Government's consideration of the costs to be recovered for the regulatory effort for the Scheme.

Stakeholder consultation regarding the *Medicinal Cannabis Program Fees and Charges Review* opened 19 December 2022 and closed 10 February 2023. This consultation period included two online webinars open to all stakeholders that registered their interest in attending. A published consultation paper available on the ODC website summarised the findings of the fees and charges review, including the proposed changes, and interested parties were encouraged to provide feedback. A high-level summary of key stakeholder feedback received specifically relevant to the revised fees and charges is attached at **Attachment A**.

Following the consultation process, and feedback provided on the revised activity-based cost recovery model by the Department of Finance (in particular to include revised salary amounts), minor increases were made to all associated fees and charges (from that provided during the public consultation) for 2023-24, as reflected in the final amounts in this CRIS.

6. Financial Estimates

Table 7 details the Program's financial estimates for the current budget year and three forward years. The estimates are based on the revised cost model and resulting fees and charges structure (implemented on 1 August 2023).

Table 7: Financial estimates for the program				
Financial Estimates	2023-24	2024-25	2025-26	2026-27
	\$'000	\$'000	\$'000	\$'000
Expenses (X)	5,298	5,552	5,747	5,965
Revenue (Y)	4,553	4,776	4,941	5,125
Balance (Y-X)	-745	- 776	-806	-840
Cumulative Balance	-\$ 745	-\$ 1,521	-\$ 2,327	-\$ 3,167
Explain balance management strategy	The Department has appropriation funding from the Australian Government to cover the cumulative balance variance resulting from partial cost recovery arrangements.			

The cumulative balance has been reset in 2023-24 with the implementation of revised cost recovery arrangements.

7. Performance

7A. Financial performance

Previous financial performance is detailed in Table 8 from pre-reform activities. While the ODC has historical data in relation to these elements, the reforms to the program mean that past financial performance to 2020-21, will not be directly comparable to the transition/review 2022-23 financial year or to the budgeted 2023-24 financial year and forward estimates of the Program, due to not fully recovering the regulatory costs of the Program. In addition, the structure of fees and charges have also changed, as has the charging model.

Table 8: Financial performance for the program					
Actual Financial Results	2018-19 Actual \$'000	2019-20 Actual \$'000	2020-21 Actual \$'000	2021-22 Actual \$'000	2022-23 Actual \$'000
Expenses (X)	2,112	3,702	4,548	5,397	5,340
Revenue (Y)	1,046	2,086	3,137	3,162	1,894
Balance (Y-X)	-1,066	-1,616	-1,411	-2,235	-3,446
Cumulative Balance	-\$ 2,259	-\$3,875	-\$ 1,411	-\$ 3,648	-7,092
Explain material variance	<p>The forecasted revenue for the 2022-23 financial year was projected to be \$7.467 million (based on the multiple licence framework), with forecasted expenses of \$7.506 million. However, actual revenue from the single licence framework was lower than expected at \$1,894 million. Actual expenses were also lower than expected at \$5.340 million.</p> <p>The variance between forecasted and actual revenue can be attributed to several factors, which were highlighted in a review conducted by the Office of Drug Control (ODC) in 2022.</p> <p>That review considered the existing medicinal cannabis cost recovery arrangements and subsequently identified that previous forecast volumes were overestimated. The review further identified charges as described did not adequately reflect the regulatory effort, thereby resulting in the ODC under charging for its activities. To address this, a new activity-based costing model was developed to calculate the appropriate fees and charges to be applied in line with the 2021 reforms that implemented a single licence framework and permit reforms. Further, as 2022-23 was a “transition/review year” adjustments to fees to reflect the new framework were not in place, therefore contributing to the significant variance between forecasted and actual revenue.</p>				
Explain balance management strategy	<p>The cumulative balance was reset in 2020-21 when revised cost recovery arrangements were implemented. The cumulative balance has again been reset in 2023-24 following the implementation of revised cost recovery arrangements.</p>				

7B. Non-financial performance

Non-Financial performance of regulatory activity over 2022-23 – Volumes

Activity	2022-23 Estimated**	2022-23 Actual	2022-23 Variance
Cannabis licence applications	16	19	+3
Cannabis permit applications	143	42	-101
Application for a variation to a cannabis licence	110	54	-56

Activity	2022-23 Estimated**	2022-23 Actual	2022-23 Variance
Application for a variation to a cannabis permit	84	9	-75
Planned inspections	25	30	+5
Annual licence charge	153	95	58

** Estimated volumes for 2022-23 were forecast based on the previous multiple licence and permit framework

Performance measures

The Act does not include statutory timeframes for decision-making or application processing. The Department provides an indicative timeline for processing applications on the ODC website, from the date of receipt. However, this excludes any time where the application is referred back to the applicant for further information, or due to delays in receiving information requested from external Commonwealth, State and Territory agencies (including law enforcement agencies). These published timeframes are currently:

- medicinal cannabis licence application - approximately 205 working days (including receipting and generating invoices)
- application to vary a medicinal cannabis licence: approximately 70 working days to 205 working days depending on the complexity of the variation submitted

In 2022 the ODC undertook a business process and systems transformation review to identify both system and process improvements allow the ODC to perform its functions in a more effective and efficient manner. Industry representatives and other stakeholders were consulted as part of the review. The review made several recommendations on the possible future state of the ODC's processes and systems. Government funding was provided in the 2023-24 Budget to progress an ODC digital transformation and process reform program of work resulting from the transformation review. This program of work will allow for the implementation of, amongst other things, the replacement of manual application submissions with smart forms, a case management system for the tracking of applications and regulatory actions, effective sharing of information across multiple software systems and data transferability, and several other system and process improvements to assist both industry and ODC staff.

International Scrutiny

The progress of the Scheme will be the subject of scrutiny from the INCB. Australia is required to provide annual datasets to the INCB outlining the quantities of cannabis plants cultivated, cannabis and cannabis resin that has been produced and cannabis drugs that have been manufactured in a calendar year.

The INCB then makes comments in its annual report on the performance of Australia against the requirements of the Single Convention. If the INCB make a negative comment on Australia's performance, for example that production of cannabis resin has exceeded the medical need, then

remedial action may need to be considered. Such an event could impact on the data provided in this document.

8. Key forward dates and events

- July 2024 - Annual update of CRIS and application of indexation to fees and charges for the 2024- 25 financial year

9. CRIS approval and change register

Date of CRIS change	CRIS change	Approver	Basis of change
21 October 2016	Certification of the CRIS	Secretary Department of Health	New regulatory charging activity
02 November 2016	Agreement of the CRIS	Minister for Health	New regulatory charging activity
10 November 2016	Approval for the CRIS release	Finance Minister	High risk rating for the new regulatory charging activity
16 April 2019	Update of financial results and estimates.	Secretary Department of Health	2016-17 and 2017-18 financial results reported. 2018-19 and forward estimates updated.
20 March 2020	Update of 2018/19 financial results	First Assistant Secretary – Regulatory Practice and Support Division	2018/19 financial results reported.
October 2020	Revision of fees and charges to reflect review of cost recovery arrangements and changes announced in 2020-21 Budget.	Minister for Health	Review of cost recovery cost recovery arrangements. Revised and new fees and charges.
July 2021	Annual update of CRIS and application of indexation to fees and charges for the 2021-22 financial year	Minister of Health and Aged Care	Annual update and review.

Date of CRIS change	CRIS change	Approver	Basis of change
December 2021	Update of 2020-21 financial results	First Assistant Secretary – Regulatory Practice and Support Division	2020/21 financial results reported.
April 2023	Annual update of CRIS for the 2022-23 financial year, including actual financial results for the 2021-22 financial year	First Assistant Secretary – Regulatory Practice and Support Division	Annual update and review.
July 2023	Revision of fees and charges to reflect review of cost recovery arrangements and changes	Assistant Minister for Health and Aged Care	Review of the cost recovery arrangements approved in the 2023 Budget.
November 2023	Update of 2022-23 financial results	First Assistant Secretary – Regulatory Practice and Support Division	2022/23 financial results reported.

Attachment A – Summary of consultation submissions

Medicinal Cannabis Program Regulatory Fees and Charges Review

Throughout the consultation period of 19 Dec 2022 – 10 Feb 2023, the Medicinal Cannabis Program Regulatory Fees and Charges Review (the Review) received direct feedback from stakeholders during 2 public consultation webinars and 6 written submissions, with 5 being relevant to the Review. Below is a high-level summary of key stakeholder feedback received specifically relevant to the revised fees and charges.

Key points from feedback

Re-categorisation of licence and permit variations, and licence and permit applications

The feedback received throughout the public consultation on the Review was positive overall, with wide support of the re-categorisation of licence and permit applications and variations, based on differing amounts of staff effort associated with each type of application. The feedback also included positive reports in relation to recently implemented reforms, including regarding the new licence application form and the single licence framework.

Changes in fees and charges

The proposed decrease in some fees and charges, including to remove some previously imposed charges, where relevant, was widely supported by stakeholders.

The proposed increases in fees and charges, where relevant, were largely accepted with the hope that assessment timelines would decrease in some instances. However, some concern was raised in written submissions regarding simultaneously increasing fees for both licences and permits, with requests for further justification and education of the increase in fees and charges. The most concern from the written feedback was in relation to the annual licence charge, and permit application fees. The impact on non-operational licence holders by the significant increase in the annual licence charge was noted in two submissions. Concern was also noted about how the increase in certain permit application fees were justified.

Some comments from stakeholders queried how the revised application types would be administered and whether multiple applications, of either the same or different types, would need to be paid for even if submitted at the same time.

The ODC notes this feedback and will ensure there is information in the CRIS and available on the website to educate stakeholders about the Australian Government Charging Framework requirements and process for determining fees and charges in accordance with activity-based costing principles. In particular, as a result of the Review, the ODC identified that some of the regulatory activities it undertakes were not appropriately accounted for by the fees and charges currently prescribed and that the revised costing model is more consistent with Government cost recovery principles.

Additionally, in relation to the application of fees for multiple applications submitted concurrently, the ODC will consider this feedback in line with the cost recovery principles.

Calls for improved, measurable, and published timeframes

The submissions included widespread acknowledgement that the increase in fees and charges would be more acceptable if there were improved levels of service. It was also widely suggested that implementation of response, processing, and assessment timeframes that are clear, transparent, and measurable should be published on the ODC website for all application types.

The ODC notes this feedback, and that the relevant information will be made more available for stakeholders. Additionally, the Budget funding provided in 2023-24 for ODC digital transformation will deliver tangible benefits for stakeholders and the ODC through better and more efficient digital systems and business processes.

Requests for Government Funding to support the industry and improve ODC's digital transformation

Half of the submissions called for greater support from the Government to help establish Australia as a key player in the medicinal cannabis global market, while acknowledging the need to review the fees and charges and an understanding of the requirement for ODC to recover costs. Two submissions recognised the need for the progression and Government funding of the ODC digital transformation program.